Nexalin Technology (NXL) Cost of Revenue (2021 - 2026)

Nexalin Technology's Cost of Revenue history runs 6 years deep, the most recent figure standing at $1817.0 for Q1 2026.

• On a quarterly basis, Cost of Revenue fell 86.6% year-over-year to $1817.0 in Q1 2026; TTM through Mar 2026 was $49632.0, a 21.07% increase from a year earlier, with the FY2025 full-year figure at $61373.0, up 67.72% from the prior year.
• Cost of Revenue retreated to $1817.0 in Q1 2026 per NXL's latest filing, from $21029.0 in the prior quarter.
• Across five years, Cost of Revenue topped out at $187298.0 in Q3 2022 and bottomed at $1817.0 in Q1 2026.
• The 5-year median for Cost of Revenue is $9156.0 (2024), against an average of $28746.1.
• Across the five-year window, Cost of Revenue soared 1912.66% in 2022 and slumped 97.88% in 2023, its largest moves.
• Year by year, Cost of Revenue stood at $6867.0 in 2022, then retreated by 23.82% to $5231.0 in 2023, then soared by 43.3% to $7496.0 in 2024, then soared by 180.54% to $21029.0 in 2025, then slumped by 91.36% to $1817.0 in 2026.
• Per Business Quant, the three latest NXL Cost of Revenue figures stand at $1817.0 (Q1 2026), $21029.0 (Q4 2025), and $3948.0 (Q3 2025).